A portfolio-based approach to meeting market needs in combination products

Leveraging insights to enable enhanced system integration

Beth DiLauri, BD

6 November 2017

Recognizing the needs of healthcare are changing…



At BD, we are aligning our capabilities to meet those needs



BD is intensively focused on developing a portfolio of solutions to meet these needs



**BD Libertas™, BD Intevia™ , BD Onbody Injector are products in development; some statements made are forward-looking that are subject to a variety of risks and uncertainties.*

Addressing challenges in delivering large volume, high viscosity biologics

BD Libertas™ wearable injector

- **No patient assembly required**
- **Delivers 2-5mL, 5-10mL & ≥50cP biologics**
- **No minimum injection time**
- **Hands-free drug delivery**
- **Single-use, disposable, prefilled container delivery system**

**BD Libertas™ is a product in development; some statements made are forward-looking that are subject to a variety of risks and uncertainties.*

Compelling solution for in-home delivery of large volume biologics



BD Libertas™ wearable injector

Maximizing Success for Pharma

- Reduces need to concentrate biologics
- Enables formulation flexibility
- Leverages BD Neopak™ technology to ensure primary container performance
- Integrated systems designed for end-to-end compatibility

Driving Confidence for Patients

- Enables ease of use through no patient assembly
- Allows for convenience of in-home administration
- Delivers dose with the push of a button
- Patient needle based on BD PentaPoint™ technology

**BD Libertas™ is a product in development; some statements made are forward-looking that are subject to a variety of risks and uncertainties.*

Seamless systems integration is critical to success of Combination Products

BD Libertas™ wearable injector

BD Libertas™ wearable injector with Smart option





*BD Libertas™ is a product in development; some statements made are forward-looking that are subject to a variety of risks and uncertainties.

De-risking development: characterizing large volume subcutaneous injections





Wednesday, 8 November 2017
Track A: Patient-Device Interface
9:30 am, Hall D

Committed to driving innovation across the volume and viscosity continuum





**BD Libertas™, BD Intevia™ and BD Onbody Injector are products in development; some statements made are forward-looking that are subject to a variety of risks and uncertainties.*

Acknowledgements